摘要
目的探讨贝伐单抗联合紫杉醇和顺铂治疗非小细胞肺癌的效果及对microRNA-99a、miRNA-145的影响。方法100例非小细胞肺癌患者,随机分为对照组和观察组,各50例。对照组使用紫杉醇和顺铂治疗,观察组使用贝伐单抗联合紫杉醇和顺铂治疗。比较两组患者的近期疗效及治疗前后microRNA-99a及miRNA-145水平变化。结果观察组总有效率(ORR)为46.00%,疾病控制率(DCR)为86.00%,均高于对照组的24.00%、68.00%,差异有统计学意义(P<0.05)。治疗前,两组microRNA-99a及miRNA-145水平比较差异无统计学意义(P>0.05);治疗后,观察组microRNA-99a及miRNA-145水平均明显高于对照组,差异有统计学意义(P<0.05)。结论贝伐单抗联合紫杉醇和顺铂治疗非小细胞肺癌的效果显著,能有效提升microRNA-99 a、miRNA-145的表达,有助于改善预后,具有积极的临床意义。
Objective To discuss the efficacy of bevacizumab combined with paclitaxel and cisplatin in the treatment of non-small cell lung cancer and analysis of the effect on microRNA-99a and miRNA-145.Methods A total of 100 non-small cell lung cancer patients were randomly divided into control group and observation group,with 50 cases in each group.The control group was treated by paclitaxel and cisplatin,and the observation group was treated by bevacizumab combined with paclitaxel and cisplatin.The short-term efficacy,and changes of microRNA-99a and miRNA-145 before and after treatment were compared between the two groups.Results The overall response rate(ORR)46.00%and disease control rate(DCR)86.00%in the observation group was higher than 24.00%and 68.00%in the control group,and their difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in microRNA-99a and miRNA-145 between the two groups(P>0.05).After treatment,the microRNA-99a and miRNA-145 in the observation group were obviously higher than those in the control group,and their difference was statistically significant(P<0.05).Conclusion Bevacizumab combined with paclitaxel and cisplatin shows remarkable efficacy in the treatment of non-small cell lung cancer,and it can effectively improve the expression of microRNA-99a and miRNA-145 and helps improve prognosis.It contains active clinical significance.
作者
李正雄
LI Zheng-xiong(Oncology Department,Shenzhen Longhua District Central Hospital,Shenzhen 518110,China)
出处
《中国实用医药》
2020年第6期99-100,共2页
China Practical Medicine
